Today we launched with an ambition to build the leading immune reset company. We are tackling immune-mediated diseases head-on by combining scientific expertise, a track record of advancing cell-depleting therapies through the clinic, and a robust pipeline. Special thanks to our investors for their commitment to this vision, including Monograph Capital, GSK, TPG, New Enterprise Associates (NEA), Norwest Venture Partners, Boyu Capital, UPMC Enterprises, LongRiver Investments and Keymed Biosciences. Read more about how we are defining the future of treatment for people with immune-mediated disease: https://lnkd.in/eMGg-q94
Ouro Medicines
Biotechnology Research
San Francisco, CA 1,183 followers
Defining the future of treatment for people with immune-mediated diseases
About us
Ouro Medicines is dedicated to developing immune reset therapeutics for people living with chronic immune-mediated diseases. Our approach is focused on leveraging T cell engagers in B cell mediated diseases to achieve immune resets that enable durable remissions without ongoing immunosuppression for patients. Based in San Francisco, Ouro was founded by Monograph Capital in partnership with GSK. We are also backed by leading investors TPG, NEA, Norwest and more.
- Website
-
www.ouromedicines.com
External link for Ouro Medicines
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Francisco, CA
- Type
- Privately Held
- Founded
- 2024
Locations
-
Primary
Get directions
San Francisco, CA, US
Employees at Ouro Medicines
-
Christina Carlson
General Counsel and Chief Administrative Officer @ Ouro Medicines | JD
-
David Chau
Head of Technical Operations
-
Kyu Hee Hong
Director of Bioanalytical Assays | Bioanalytical Strategy, Method Development
-
John Davis
Pharma/Biotech Executive & Strategic Advisor, Board of Directors Member, Scientific Advisory Board Member